On Wednesday, sleep apnoea treatment manufacturer ResMed (ASX: RMD) revealed strong second quarter results including a 17% increase in revenue compared to the same period of the prior year. In announcing the results, ResMed chief executive Mick Farrell said the company was well positioned to adapt to the Trump administration’s protectionist policies due to its US-based manufacturing operations. RMD shares closed up 9.8% for the week. We hold RMD as a research-driven investment in the WAM Leaders portfolio.
Please sign in to comment on this wire.